BiologicalDrug
Aluminum Hydroxide clinical trials
Also written Alhydrogel.
- studies test it
- 13
- open now
- 1
- in phase 3
- 0
- first study started
- 1998
Keep track of what changes. Save the Aluminum Hydroxide studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
11 studies that test it; most in 2006 (3); 1 more planned to start later
| Year | Studies |
|---|---|
| 1998 | 1 |
| 2006 | 3 |
| 2011 | 1 |
| 2016 | 2 |
| 2020 | 2 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 12
- Phase 2
- 3
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 1 · Other 12
National Institute of Allergy and Infectious Diseases (NIAID) (7) · Institut National de la Santé Et de la Recherche Médicale, France (1) · Spero Therapeutics (1) · University Hospital Tuebingen (1) · University of Alabama at Birmingham (1) · HIV Vaccine Trials Network (1) · University of Oxford (1)
Often tested with
Tested in the same studies.
TLR4 Agonist G100 (2) · MEDI9197 (2) · BG505 (1) · TRIMER 4571 (1) · Magnesium Hydroxide (1) · Simethicone (1) · Omeprazole (1) · Sargramostim (1)
Studies
Open first, then newest update. How each study uses Aluminum Hydroxide is read from its arms, and is right about nine times in ten.
Testing it · 13
- Safety & Immunogenicity of 426c.Mod.Core-C4b Vaccine With 3M-052-AF+Alum in Infants Perinatally Exposed to HIV But UninfectedNot yet recruitingPhase 1HIV Vaccine Trials NetworkNCT06613789Written as Aluminum hydroxide suspension (Alum)
- Trial to Evaluate the Safety and Immunogenicity of a Placental Malaria Vaccine Candidate (PRIMVAC ) in Healthy AdultsCompletedPhase 1Institut National de la Santé Et de la Recherche Médicale, FranceNCT02658253Written as Alhydrogel
- Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected AdultsCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT04177355Written as Alum (Aluminum Hydroxide Suspension)
- A Clinical Trial in Adult Participants Without HIV and in Overall Good Health to Evaluate the Safety and Immunogenicity of CD4BS CH505M5 Pr-NP1 Followed by CH505 TF chTrimer Boost Both Adjuvanted With Either Lipid Nanoparticles (LNPs) or 3M-052-AF + AlumWithdrawnPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT06267872Written as Aluminum Hydroxide Suspension (Alum)
- KLH Challenge to Explore the Human Immune ResponseStatus unknownNot applicableUniversity of OxfordNCT05876195Written as Alhydrogel
- Study to Examine the Effect of Antacid and Omeprazole on the Single-Dose Pharmacokinetics of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Healthy Adult SubjectsCompletedPhase 1Spero TherapeuticsNCT04368585Written as 20 mL aluminum hydroxide/magnesium hydroxide/simethicone (400 mg aluminum hydroxide/400 mg magnesium hydroxide/40 mg simethicone per 5 mL)
- Safety and Immunogenicity of the Placental Malaria Vaccine Candidate PAMVAC Variously AdjuvantedCompletedPhase 1University Hospital TuebingenNCT02647489Written as Alhydrogel
- Phase I STEBVax in Healthy AdultsCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00974935Written as Aluminum hydroxide
- H5 Vaccine Alone or With Aluminum Hydroxide in Elderly AdultsCompletedPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT00294099Written as Aluminum hydroxide
- Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV MelanomaCompletedPhase 1/2University of Alabama at BirminghamNCT00004184Written as alum adjuvant
- Phase I Dose Escalation SARS-CoV Recombinant S Protein, With and Without Adjuvant, Vaccine StudyWithdrawnPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT01376765Written as Aluminum hydroxide adjuvant (Alhydrogel®)
- Dose-Escalating Trial Using Vero Cell-culture Derived H5N1 +/- Aluminum in AdultsCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00382980Written as Aluminum hydroxide
- H5 Vaccine Alone or With Adjuvant in Healthy AdultsCompletedPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT00296634Written as Aluminum hydroxide
Given in every arm · 8 — Aluminum Hydroxide is usual care beside what is tested
- A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular RoutesActive, not recruitingPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT07221162Written as Aluminum Hydroxide Suspension
- Evaluating the Safety and Immunogenicity of Stabilized CH505 TF chTrimer in Healthy, HIV-uninfected Adult Participants.CompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT04915768Written as Aluminum hydroxide suspension
- Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral TherapySuspendedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT06680479Written as Aluminum Hydroxide Suspension
- Evaluating the Safety and Immunogenicity of an HIV Vaccine (gp145 C.6980) in Healthy, HIV-Uninfected Adults in the United StatesCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT03382418Written as Aluminum Hydroxide Adjuvant
- Evaluating the Safety, Tolerability, and Immunogenicity of a Tetravalent Dengue Vaccine (V180) in Healthy Adults Who Previously Received a Live-Attenuated Tetravalent Vaccine (TV003 or TV005)CompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT02450838Written as Alhydrogel™
- H5 Adult - Chiron Study of Bird Flu VaccineCompletedPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT00280033Written as Aluminum hydroxide
- ICC-1132 - Candidate Vaccine Against P Falciparum MalariaCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00587249Written as Alhydrogel
- SARS Coronavirus Vaccine (SARS-CoV)WithdrawnPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00533741Written as Aluminum hydroxide
As the comparator · 1 — what is tested is compared with Aluminum Hydroxide
Codes
What other systems call Aluminum Hydroxide · ClinicalTrials.gg INT006935
- MeSH (NLM) D000536Aluminum HydroxideConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 5QB0T2IUN0ALUMINUM HYDROXIDEConfirmed FDA, NLM, Wikidata
- RxNorm 81948Confirmed FDA, Wikidata
- Wikidata Q407125aluminum hydroxideConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C39707Aluminum HydroxideOne source FDA
- DrugBank DB06723One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000536 | Aluminum Hydroxide | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 5QB0T2IUN0 | ALUMINUM HYDROXIDE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 81948 | — | Confirmed FDA, Wikidata |
| Wikidata | Q407125 | aluminum hydroxide | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C39707 | Aluminum Hydroxide | One source FDA |
| DrugBank | DB06723 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.